Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: tom rusnak who wrote (83846)	9/28/2000 10:39:55 PM
From: Knighty Tin	Read Replies (1) \| Respond to of 132070

Tom, the great majority of small biotech cos. runup going into expected FDA approval and get killed if they receive anything less than carte blanche. That is just the way the game is played. They also tend to run up before Phase I and Phase II results are announced, which is flat out silly. But, if you have a stock the size of Amgen, the moves are muted. Sonus is more of a device co. than a true biotech. They've had some problems with patients, so I've avoided them. However, the delivery technology sounds good if they ever get the kinks out.